Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MILLIE D LONG

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1336101914
CMS profile
1056079
Location
CHAPEL HILL, NC

General Payments · PY2018–2024

$342,101.49

  • Reported across 288 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$47,908.88

27 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $14,400.00 5
INTERCEPT PHARMACEUTICALS, INC. $11,203.25 3
Janssen Biotech, Inc. $8,491.20 6
PFIZER INC. $4,626.00 1
Takeda Pharmaceuticals U.S.A., Inc. $3,510.80 4
ABBVIE INC. $3,145.98 4
Celltrion USA Inc. $2,498.89 2
Medtronic, Inc. $18.17 1
Ipsen Biopharmaceuticals, Inc $14.59 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $74,868.64 95
PY2019 $63,154.09 62
PY2020 $25,163.40 14
PY2021 $49,451.90 23
PY2022 $15,419.00 18
PY2023 $66,135.58 49
PY2024 $47,908.88 27

Payment records · PY2024 (27)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $1,625.00 02/13/2024 Consulting Fee Undisputed 01/23/2026 1104898859 CMS
ABBVIE INC. $120.98 03/16/2024 Food and Beverage Undisputed 01/23/2026 1104898861 CMS
ABBVIE INC. $700.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 1104898863 CMS
ABBVIE INC. $700.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1104898865 CMS
Celltrion USA Inc. $2,445.00 10/27/2024 Consulting Fee Undisputed 01/23/2026 1075854567 CMS
Celltrion USA Inc. $53.89 10/27/2024 Food and Beverage Undisputed 01/23/2026 1075854569 CMS
Eli Lilly and Company $800.00 03/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135209802 CMS
Eli Lilly and Company $6,400.00 05/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135173708 CMS
Eli Lilly and Company $2,800.00 05/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135209183 CMS
Eli Lilly and Company $1,600.00 05/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135235676 CMS
Eli Lilly and Company $2,800.00 05/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135256357 CMS
Intercept Pharmaceuticals, Inc. $5,100.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1113639531 CMS
Intercept Pharmaceuticals, Inc. $2,000.00 11/08/2024 Travel and Lodging Undisputed 01/23/2026 1113639533 CMS
Intercept Pharmaceuticals, Inc. $4,103.25 11/08/2024 Consulting Fee Undisputed 01/23/2026 1113639535 CMS
Ipsen Biopharmaceuticals, Inc $14.59 09/06/2024 Food and Beverage Undisputed 01/23/2026 1091988283 CMS
Janssen Biotech, Inc. $3,612.50 04/29/2024 Consulting Fee Undisputed 01/23/2026 1078819483 CMS
Janssen Biotech, Inc. $146.28 05/17/2024 Food and Beverage Undisputed 01/23/2026 1078819378 CMS
Janssen Biotech, Inc. $19.00 05/17/2024 Food and Beverage Undisputed 01/23/2026 1078819609 CMS
Janssen Biotech, Inc. $2,550.00 05/24/2024 Consulting Fee Undisputed 01/23/2026 1078819790 CMS
Janssen Biotech, Inc. $38.42 12/07/2024 Food and Beverage Undisputed 01/23/2026 1078819479 CMS
Janssen Biotech, Inc. $2,125.00 12/21/2024 Consulting Fee Undisputed 01/23/2026 1078819641 CMS
Medtronic, Inc. $18.17 07/11/2024 Food and Beverage Undisputed 01/23/2026 1119269824 CMS
PFIZER INC. $4,626.00 06/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1131996217 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,356.00 02/19/2024 Consulting Fee Undisputed 01/23/2026 1137623143 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,034.00 10/22/2024 Consulting Fee Undisputed 01/23/2026 1137623147 CMS
Takeda Pharmaceuticals U.S.A., Inc. $105.30 10/28/2024 Food and Beverage Undisputed 01/23/2026 1137623151 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.50 12/09/2024 Food and Beverage Undisputed 01/23/2026 1137623155 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.